NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing ...
Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium will retain 100% ownership ...
Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the first quarter of 2021 and to be completed by the end of the second quarter of 2021 NEW YORK, Dec. 15, 2020 ...
NEW YORK, July 02, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical ...
MIAMI and SOLANA BEACH, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress ...
Halo 2 provides food suppliers with a traceable and auditable testing procedure, satisfying retailer Codes of Practice and reduces manual testing time. It can be installed on Fortress throat, pipeline ...
The Interceptor was designed to tackle the challenge of high product rejects when using metal detectors to inspect meat, dairy, ready meals, bakery and fortified cereals applications, said the firm.
Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the fourth quarter of 2020 NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback